<DOC>
	<DOC>NCT01548820</DOC>
	<brief_summary>On treatment parameters for Lamivudine resistance in HBV treated Egyptian patients</brief_summary>
	<brief_title>Resistance to Lamivudine in HBV Egyptian Patients</brief_title>
	<detailed_description>Primarily: To study the correlations between the following parameters in adult Egyptian patients with chronic viral hepatitis B before treatment: - ALT. - HBeAg. - HBV-DNA by quantitative PCR. - Biopsy (if possible). Secondarily: After receiving lamivudine therapy we will identify the impact of these parameters on viral breakthrough at 1 year of therapy.</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B, Chronic</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Adult patients &gt;18 years old Egyptian nationality Positive serology for HBsAg for more than 6 months Positive HBV viremia (above 2000IU/ml). Lamivudine monotherapy AntiHBcIgM seropositivity Positive serology for HCV Positive serology for HDV Patients complicated with HCC</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Hepatitis B virus</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>Resistance to treatment</keyword>
</DOC>